← SynDRA
H3B-6527
SynDRA canonical compound SYN0038655 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | FGFR4 |
|---|
| Mechanism of action | fgfr inhibitor |
|---|
| Indication | hepatocellular carcinoma (hcc) |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- fgfr inhibitor
- FGFR4 INHIBITOR
Cross-references
Synonyms
- MBWRLLRCTIYXDW-UHFFFAOYSA-N
- UNII-4HTE364XIK
- 4HTE364XIK
- N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide
- Eisai/H3 Biomedicine
- CHEMBL3939295
- SCHEMBL16659467
- BDBM249396
- EX-A1510
- BCP17555
- ZINC521836463
- AKOS032960479
- H3B6527
- CS-5830
- ACN-037543
- AK684091
- AC-29878
- HY-100491
- US9434697, 108
- N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acryla
- RefChem:144964
- FGFR4 INHIBITOR H3B-6527
- Fibroblast Growth Factor Receptor 4 Inhibitor H3B-6527
- MFCD30377210
- C29H34Cl2N8O4
- orb1299550
- SCHEMBL29412748
- SCHEMBL30274661
- GLXC-10718
- H3B 6527 [WHO-DD]
- NSC800283
- s8675
- CCG-270286
- EBC-220150
- NSC-800283
- SB40408
- AS-55996
- H3B-6527?
Look up H3B-6527 in the interactive SynDRA portal →